Compare · NVO vs QUCY
NVO vs QUCY
Side-by-side comparison of Novo Nordisk A/S (NVO) and Mainz Biomed N.V. (QUCY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and QUCY operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $188.38B, about 4055.9x QUCY ($46.4M).
- Over the past year, NVO is down 46.8% and QUCY is down 0.5% - QUCY leads by 46.3 points.
- QUCY has been more active in the news (25 items in the past 4 weeks vs 8 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 0 for QUCY).
- Company
- Novo Nordisk A/S
- Mainz Biomed N.V.
- Price
- $42.19+2.89%
- $2.04-2.86%
- Market cap
- $188.38B
- $46.4M
- 1M return
- -8.44%
- +487.56%
- 1Y return
- -46.83%
- -0.49%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 8
- 25
- Recent ratings
- 25
- 0
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care
Latest QUCY
- Quantum Cyber Signs LOI to Acquire an Estimated 43,000 Square Foot U.S.-Based Manufacturing Facility to Support Mass-Scale Autonomous Drone Production
- Mainz Biomed N.V. filed SEC Form 8-K: Termination of a Material Definitive Agreement
- SEC Form S-3 filed by Mainz Biomed N.V.
- Drones-as-a-Service Market Surges as AI, Automation, and Industrial Demand Drive Billion-Dollar Growth
- Mainz Biomed N.V. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
- Quantum Cyber Publishes Inaugural Corporate Investor Presentation Showcasing System-of-Systems Autonomous Defense Platform, Eight Filed Patent Positions, LOIs With General Cherry and SOCOM, and $15 Million Debt-Free Balance Sheet
- Quantum Cyber Assumes Direct Manufacturing of Autonomous Drone; Expands BP United Agreement
- SEC Form DEF 14A filed by Mainz Biomed N.V.
- Mainz Biomed N.V. filed SEC Form 8-K: Other Events
- Quantum Cyber Announces Plans to Establish U.S.-Based Defense-Technology Manufacturing Complex to Support Drone and Autonomous Systems Delivery